Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.

This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.

In this systematic review and meta-analysis, researchers evaluated the link between alopecia areata and adverse pregnancy outcomes, motivated by the condition's association with other autoimmune diseases that increase pregnancy risks. Results are not provided in the abstract.

This study found that in Chinese women with PCOS, pretreatment with ethinylestradiol/cyproterone acetate was associated with a lower risk of gestational diabetes, pregnancy-induced hypertension, and premature delivery compared to those without pretreatment.

This study in neonatal rats found that inhibiting neurosteroid synthesis with finasteride unexpectedly reduced the severity and duration of neonatal seizures following birth asphyxia, maintained cognitive functions, but increased anxiety-like behaviors, highlighting a complex role of neurosteroids in hypoxic-ischemic encephalopathy outcomes.

This study found that low serum testosterone and elevated serum oestrone in men with cirrhosis are associated with worse liver disease and adverse health outcomes, suggesting oestrone as a potential ill health marker.

This study reports a novel diagnostic method for latent circadian rhythm sleep-wake disorder using circadian gene oscillations from hair follicle cells to improve sleep disorder differentiation and potential therapeutic intervention.

This narrative review explores current evidence on GLP-1 receptor agonists and hair-related conditions, noting reports of both hair regrowth and potential associations with telogen effluvium.

GLP-1 receptor agonists may help or harm hair health, needing more research.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

This case series reports on five cats who experienced moderate to severe skin reactions after receiving the frunevetmab injection, noting pruritus, alopecia, and ulcerations developing within days of treatment.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

This study reviews the biology and cosmetic treatment of hair, emphasizing future advancements in safer, more effective procedures to meet consumer needs for hair care.

This paper discusses mechanisms by which various chemicals disrupt male sexual differentiation, concluding that mixture risk assessments should include a broader set of compounds beyond phthalates to address cumulative reproductive health risks.

This article describes how a new blood glucose management service at the NIH Clinical Center improved safety and patient outcomes for hospitalized patients with diabetes.

Minoxidil is effective for hair growth and safe for long-term use.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

In this study, infants born to mothers with alopecia areata had a higher risk of adverse birth outcomes, including preterm birth, low birth weight, Caesarean section, and congenital malformations.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This study found that hormone replacement therapy was associated with reduced COVID-19 mortality and adverse outcomes in nonimmunosuppressed postmenopausal women and immunocompromised male solid organ transplant recipients.

This review discusses the diagnosis and management of severe cutaneous adverse reactions to drugs and provides guidance for physicians to improve patient outcomes, but it reports no new clinical results.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

In this study, adult hereditary angioedema patients treated with lanadelumab at a Spanish hospital had a 94.1% reduction in angioedema episodes and needed 61% less on-demand medication, showing improved quality of life and minimal adverse effects.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

The study on androgenetic alopecia reported that microneedling with concentrated growth factor significantly improved hair regrowth in patients over two years, without age influencing the outcome, and recorded no significant adverse reactions.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.